|
NanoInk, Inc., a company specialising in nanometre-scale manufacturing and applications development for the life science and semiconductor industries, today announced the election of Alan F. Holmer to the Company’s Board of Directors.
Mr Holmer was elected by NanoInk’s current Board of Directors as the company seeks to add seasoned board members with industry experience. With the addition of Mr Holmer, the NanoInk Board will now consist of six members.
Mr Holmer, aged 56, is the former President and Chief Executive Officer of the Pharmaceutical Research and Manufacturers of America (PhRMA), where he spent nearly ten years leading this well-known organisation that represents the interests of leading pharmaceutical and biotechnology companies. He also serves as a member of the Presidential Advisory Council on HIV and AIDS and on the Board of Directors of Inspire Pharmaceuticals.
In addition to his pharmaceutical industry experience, Mr Holmer has significant expertise in dealing with legal, international trade and governmental issues, having held various positions within the Office of the US Trade Representative, the Commerce Department and the White House, including serving as Deputy US Trade Representative with the rank of Ambassador. Mr Holmer also served as a partner at the international law firm, Sidley & Austin (now Sidley Austin Brown & Wood LLP), and as an associate at Steptoe & Johnson LLP. Mr Holmer serves on the boards of several organisations, including the Board of Trustees of the Metropolitan Washington, DC Chapter of the Cystic Fibrosis Foundation. Mr Holmer received an AB degree from Princeton University and a JD from Georgetown University.
Mr Holmer said, “NanoInk’s cutting edge technology has the potential to improve significantly the way pharmaceutical companies protect their brands from counterfeiting and diversion.”
“With his knowledge of the pharmaceutical industry and related public policy issues, Alan Holmer brings a unique expertise to our Board of Directors,” said Cedric Loiret-Bernal, MD, President and Chief Executive Officer of NanoInk. “Mr Holmer will be invaluable in helping NanoInk establish an optimal strategy for the pharmaceutical industry, regulatory and enforcement agencies to prevent counterfeiting and illegal diversion on a global basis.”
|
All News